“We definitely don't have a clear standard,” says Shawn Dason, MD, FRCSC.
In this video, Shawn Dason, MD, FRCSC, discusses the factors that urologists should consider when counseling patients with upper tract urothelial carcinoma about neoadjuvant and adjuvant treatment options. These insights stem from a study that was presented at the 2022 Society of Women in Urology Annual Clinical Mentoring Conference. Dason is a urologic oncologist and an assistant professor of urology at The Ohio State University in Columbus.
FDA approves nivolumab plus cisplatin/gemcitabine in urothelial carcinoma
March 7th 2024The approval is based on data from the phase 3 CheckMate-901 trial, which demonstrated improved overall survival and progression-free survival with the nivolumab-combination therapy vs cisplatin/gemcitabine alone.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.